Adamis Pharmaceuticals Corp
NASDAQ:ADMP
Intrinsic Value
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. [ Read More ]
The intrinsic value of one
ADMP
stock under the Base Case scenario is
4.5989
USD.
Compared to the current market price of 0.4901 USD,
Adamis Pharmaceuticals Corp
is
Undervalued by 89%.
ADMP's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ADMP or that its price is influenced by factors unrelated to fundamentals.
Adamis Pharmaceuticals Corp's market capitalization is 1.4m USD.
ADMP stock price is 0.4901 USD.
ADMP stock price (0.4901 USD) is 89% less than its Intrinsic Value (4.5989 USD).
ADMP. Open DCF Valuation
ADMP stock price (0.4901 USD) is 89% less than its Relative Value (4.5989 USD). Open Relative Valuation
ADMP has downside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
ADMP's Revenue has grown by an exceptional 115% over the past 12 months.
ADMP has negative Operating Income for the last twelve months.
ADMP has negative Net Income for the last twelve months.
ADMP's ROE (Return on Equity) for the past 12 months is very high and is equal to 4 069%.
ADMP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 311%.
ADMP has negative Gross Profit for the last twelve months.
ADMP has negative Free Cash Flow for the last twelve months.
ADMP's long-term liabilties (16m USD) exceed its long-term assets (5m USD).
ADMP's short-term liabilties (15m USD) exceed its short-term assets (3m USD).
ADMP has very high three-year average ROE (Return on Equity): 1 356%. The company is very efficient at transforming stockholders' equity into net income.
ADMP has negative three-year average ROIC (Return on Invested Capital): -437%. The company is not efficient at using invested capital to generate operating income.
ADMP's D/E (Debt to Equity) is very low and is equal to 0.
ADMP's Altman Z-Score is very low and is equal to -45.17.
Valuation Backtest
Adamis Pharmaceuticals Corp
Run backtest to discover the historical profit from buying and selling
ADMP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Adamis Pharmaceuticals Corp
Balance Sheet Decomposition
Adamis Pharmaceuticals Corp
| Current Assets | 9.3m |
| Cash & Short-Term Investments | 1.1m |
| Receivables | 1.1m |
| Other Current Assets | 7.1m |
| Non-Current Assets | 1.7m |
| PP&E | 1.6m |
| Other Non-Current Assets | 52.2k |
| Current Liabilities | 11.4m |
| Accounts Payable | 7.9m |
| Accrued Liabilities | 2.2m |
| Other Current Liabilities | 1.3m |
| Non-Current Liabilities | 185.7k |
| Other Non-Current Liabilities | 185.7k |
Earnings Waterfall
Adamis Pharmaceuticals Corp
|
Revenue
|
4.8m
USD
|
|
Cost of Revenue
|
-6.2m
USD
|
|
Gross Profit
|
-1.4m
USD
|
|
Operating Expenses
|
-23.6m
USD
|
|
Operating Income
|
-25.1m
USD
|
|
Other Expenses
|
-1.4m
USD
|
|
Net Income
|
-26.5m
USD
|
Free Cash Flow Analysis
Adamis Pharmaceuticals Corp
ADMP Profitability Score
Profitability Due Diligence
Adamis Pharmaceuticals Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Adamis Pharmaceuticals Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ADMP Solvency Score
Solvency Due Diligence
Adamis Pharmaceuticals Corp's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Adamis Pharmaceuticals Corp's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADMP Price Targets Summary
Adamis Pharmaceuticals Corp
According to Wall Street analysts, the average 1-year price target for
ADMP
is 0.42 USD
.
Ownership
ADMP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ADMP Price
Adamis Pharmaceuticals Corp
| Average Annual Return | -25.57% |
| Standard Deviation of Annual Returns | 39.2% |
| Max Drawdown | -100% |
| Market Capitalization | 1.4m USD |
| Shares Outstanding | 2 662 630 |
| Percentage of Shares Shorted | 1.3% |
Company Profile
Adamis Pharmaceuticals Corp
Country
Industry
Market Cap
Dividend Yield
Description
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The firm is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, which is used in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which is used in the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates include ZIMHI (naloxone) Injection, which is used for the treatment of opioid overdose; and Tempol (APC-400), an investigational drug, which is used in the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection. The company also has a microbicide product candidate, named C31G.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADMP
stock under the Base Case scenario is
4.5989
USD.
Compared to the current market price of 0.4901 USD,
Adamis Pharmaceuticals Corp
is
Undervalued by 89%.
You don't have any saved screeners yet
